Galderma Group AG (XSWX:GALD) Tax Expense: CHF22 Mil (TTM As of Dec. 2025)


XSWX:GALD Galderma Group AG XSWX:GALD
15 GF Score
Price CHF178.25
! 4 Warning Signs
View Full Analysis

What is Galderma Group AG Tax Expense?

Galderma Group AG XSWX:GALD -0.14% 15 Tax Expense is CHF22 Mil as of Dec. 2025. GuruFocus rates XSWX:GALD with a GF Score™ of 15/100. The stock has 4 warning signs investors should review.

Galderma Group AG's tax expense for the months ended in Dec. 2025 was CHF-26 Mil. Its tax expense for the trailing twelve months (TTM) ended in Dec. 2025 was CHF22 Mil.


Galderma Group AG  (XSWX:GALD) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Galderma Group AG Tax Expense Related Terms


Galderma Group AG Tax Expense Historical Data

* Premium members only.

The historical data trend for Galderma Group AG's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galderma Group AG Tax Expense Chart

Galderma Group AG Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Tax Expense
4.24 41.92 58.81 70.44 20.72

Galderma Group AG Semi-Annual Data
Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Tax Expense Get a 7-Day Free Trial 76.97 26.81 43.69 47.17 -25.50
XSWX:GALD
15GF Score
Galderma Group AG XSWX:GALD
Tax Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Galderma Group AG Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Expense →
What does a Tax Expense of CHF22 Mil mean?
Galderma Group AG (XSWX:GALD) has a Tax Expense of CHF22 Mil as of Dec. 2025. Tax expense is the amount of tax the company pays in an accounting period. View historical data on Galderma Group AG and its competitors.
Is Galderma Group AG's Tax Expense too high?
Galderma Group AG's current Tax Expense is CHF22 Mil. Overall, Galderma Group AG has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's Tax Expense compare to ZTS and UTHR?
Galderma Group AG's Tax Expense of CHF22 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Expense for a Drug Manufacturers company?
A good Tax Expense depends on the Drug Manufacturers industry context. However, Tax Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Expense mean?
A high Tax Expense can signal that a stock is expensive relative to its fundamentals. Tax expense is the amount of tax the company pays in an accounting period. View historical data on Galderma Group AG and its competitors. Galderma Group AG's current Tax Expense is CHF22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (XSWX:GALD) has a current Tax Expense of CHF22 Mil. The current Tax Expense is CHF22 Mil. Galderma Group AG's overall GF Score™ is 15/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Expense calculated?
Tax Expense is calculated from a company's financial statements. For Galderma Group AG (XSWX:GALD), the current Tax Expense is CHF22 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Galderma Group AG Business Description

Address Zahlerweg 10, Zug, CHE, 6300
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
15GF Score

Get the complete analysis for XSWX:GALD

Tax Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF178.25
Price